TD Private Client Wealth LLC Grows Stake in Hologic, Inc. (NASDAQ:HOLX)

TD Private Client Wealth LLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 47.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,115 shares of the medical equipment provider’s stock after purchasing an additional 2,290 shares during the period. TD Private Client Wealth LLC’s holdings in Hologic were worth $513,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. General Partner Inc. acquired a new position in Hologic during the 4th quarter valued at approximately $26,000. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. EverSource Wealth Advisors LLC raised its stake in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research analyst reports. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Wolfe Research started coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, Citigroup lowered their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Up 0.7 %

Shares of NASDAQ:HOLX opened at $61.89 on Tuesday. The business’s 50 day moving average price is $65.89 and its 200-day moving average price is $73.81. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67. The firm has a market capitalization of $13.89 billion, a price-to-earnings ratio of 19.52, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.